TEL | Jotup

Adversa AI Named an IDC Innovator in AI Security, 2024

Retrieved on:

Friday, April 5, 2024

Continuity, Doc, Research, IDC, AI, LLM, Injection, Privacy, TEL, Medical device

TEL AVIV, Israel, April 5, 2024 /PRNewswire/ -- Adversa AI has been recognized as an IDC Innovator in the report IDC Innovators: AI Security, 2024 – Part 1 (Doc #US51886324, March 2024)

Key Points:

TEL AVIV, Israel, April 5, 2024 /PRNewswire/ -- Adversa AI has been recognized as an IDC Innovator in the report IDC Innovators: AI Security, 2024 – Part 1 (Doc #US51886324, March 2024)
IDC is known for its comprehensive research and impartial insights in various tech domains, especially in growing markets.
The report comes when businesses are massively adopting LLM, pointing towards an imminent necessity for pre-production AI security assessment and further post-production protection for AI-driven applications
With its innovative AI Security Platform, Adversa AI has made significant strides with recent LLM security and continuous LLM Red Teaming capabilities.
"We are honored to be named an IDC Innovator in AI Security.
For more insights into Adversa AI's Continuous AI Red Teaming , interested parties are encouraged to contact the company directly or via their website.

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Retrieved on:

Monday, March 25, 2024

TEL AVIV, Israel, March 25, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today reported that the European Patent Office has granted a new patent for CM-101, Chemomab’s first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive fibrosis and inflammation. CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis (PSC). Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024.

Key Points:

CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis (PSC).
Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024.
The new European patent covers the use of CM-101 and sequence-related anti-CCL24 antibodies for the treatment of hepatic (liver) diseases, including PSC.
Unlike other drugs in development for PSC, CM-101 has a unique dual mechanism of action that simultaneously blocks fibrosis and inflammation.

Chargeflow Announces Virtual Event Dedicated To Evolution of Direct-To-Consumer Business Models, eCommerce Strategies, and The Future Of Payment Technologies

Retrieved on:

Monday, March 25, 2024

E-commerce, Machine learning, DTC, TEL, AI, Security (finance)

ET, “Shaping the Future of DTC in 2024” will explore the evolving landscape of Direct-to-Consumer (DTC) business models, eCommerce strategies, and the future of payment technologies.

Key Points:

ET, “Shaping the Future of DTC in 2024” will explore the evolving landscape of Direct-to-Consumer (DTC) business models, eCommerce strategies, and the future of payment technologies.
The event will spotlight leading eCommerce founders, which include:
“If there is one constant in eCommerce, it’s change.
Innovations and business models are always evolving to meet the changing preferences of customers, and keeping up with the latest developments is a daunting challenge,” said Ariel Chen, CEO and Co-founder of Chargeflow.
“With our Shaping the Future of DTC event, some of the top visionaries in the space will gather to share their insights into everything from the latest payment models to the role of AI and machine learning, as well as what to expect looking forward.

REE Automotive P7-C Receives CARB Certifications

Retrieved on:

Monday, March 25, 2024

Certification, Greenhouse gas, GHG, Power, ZEP, REE, FMVSS, EPA, California Air Resources Board, CARB, TEL, Rare-earth element

TEL AVIV, Israel, March 25, 2024 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (Nasdaq: REE), an automotive technology company and provider of full by-wire electric trucks and platforms, which recently announced FMVSS (Federal Motor Vehicle Safety Standards) and EPA (Environmental Protection Agency) certification, today announced it has received two certifications from California Air Resources Board (“CARB”) on the Class 4 P7-C chassis cab. The two certifications include (1) Phase 2 Greenhouse Gas (“GHG”) covering the complete vehicle and (2) the new Zero Emission Powertrain (“ZEP”) certification. In addition to California, several other states are expected to adopt the Phase 2 GHG and ZEP requirements in the coming years.

Key Points:

TEL AVIV, Israel, March 25, 2024 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (Nasdaq: REE), an automotive technology company and provider of full by-wire electric trucks and platforms, which recently announced FMVSS (Federal Motor Vehicle Safety Standards) and EPA (Environmental Protection Agency) certification, today announced it has received two certifications from California Air Resources Board (“CARB”) on the Class 4 P7-C chassis cab.
The two certifications include (1) Phase 2 Greenhouse Gas (“GHG”) covering the complete vehicle and (2) the new Zero Emission Powertrain (“ZEP”) certification.
CARB certification is a requirement for eligibility for several state incentives, which combined with federal can total over $100,000 per vehicle depending on customer location.
“Being CARB certified unlocks many doors for us and for our customers as we can now sell in California, and I am excited for our California dealers as they start to receive their Powered by REE trucks,” said Daniel Barel, CEO and co-founder of REE Automotive.

ParaZero Announces 2023 Financial Results

Retrieved on:

Friday, March 22, 2024

Research, Environment, Growth, EASA, Nitrox, Partnership, Black Square, Travel, IPO, Insurance, D&O, OEM, European, Safety, KULR, Marketing, TEL

TEL AVIV, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the "company” or “ParaZero”), an aerospace company focused on drone technologies for commercial drones, defense drones, and urban air mobility aircraft, reported today its financial results for year ended December 31, 2023.

Key Points:

TEL AVIV, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the "company” or “ParaZero”), an aerospace company focused on drone technologies for commercial drones, defense drones, and urban air mobility aircraft, reported today its financial results for year ended December 31, 2023.
ParaZero closed its IPO on July 31, 2023, issuing 1,950,000 ordinary shares.
ParaZero's CEO, Boaz Shetzer, stated, "2023 was a crucial year for ParaZero, as we continued to push the boundaries of innovation in drone safety.
Full Year 2023 Financial Highlights:
Sales increased by $60,390, or 10.8% to $620,508 for the year ended December 31, 2023, compared to $560,118 for the year ended December 31, 2022.

REE Automotive Announces Date for Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call

Retrieved on:

Friday, March 22, 2024

Webcast, PIN, Participation, REE, TEL, URL

TEL AVIV, Isreal, March 22, 2024 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (Nasdaq: REE) (“REE” or the “Company”), an automotive technology company and provider of full by-wire electric trucks and platforms, will release its fourth quarter and fiscal year 2023 financial results before market open on Wednesday, March 27, 2024.

Key Points:

TEL AVIV, Isreal, March 22, 2024 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (Nasdaq: REE) (“REE” or the “Company”), an automotive technology company and provider of full by-wire electric trucks and platforms, will release its fourth quarter and fiscal year 2023 financial results before market open on Wednesday, March 27, 2024.
A webcast and conference call will be held on the same date at 8:30 a.m.
ET to review the Company’s financial results for the fourth quarter and fiscal year 2023, discuss recent events and conduct a question-and-answer session.
The live webcast of the conference call can be accessed on the Investors section of the Company’s website at investors.ree.auto.

SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research

Retrieved on:

Thursday, March 21, 2024

Central nervous system, Drug discovery, Therapy, Mitochondrion, TEL, Cancer, Pharmaceutical industry

TEL AVIV, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that MitoCareX Bio Ltd. ("MitoCareX"), the Company’s venture with Dr. Alon Silberman that focuses on drug discovery and the development of cancer therapeutics by targeting the mitochondrial SLC25 protein family, had virtually screened millions of small molecules by using its computationally advanced drug discovery platform, which resulted in the identification of several molecules that could be used for potential anti-cancer treatments.

Key Points:

TEL AVIV, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that MitoCareX Bio Ltd. ("MitoCareX"), the Company’s venture with Dr. Alon Silberman that focuses on drug discovery and the development of cancer therapeutics by targeting the mitochondrial SLC25 protein family, had virtually screened millions of small molecules by using its computationally advanced drug discovery platform, which resulted in the identification of several molecules that could be used for potential anti-cancer treatments.
As previously announced by the Company on March 12, 2024, by using its in-vitro screening systems related to the mitochondria, MitoCareX corroborated its virtual findings by confirming the anti-cancer biological activity of several small molecule structures.
Additionally, by utilizing the extensive virtual data generated, MitoCareX is working towards creating a predictive AI model.
This model is expected to enable MitoCareX to navigate broader chemical spaces more efficiently, with the goal of uncovering more novel anti-cancer scaffolds that target its SLC25 protein of interest.

IONIX Advances Industry Leading Attack Surface Management Platform With Centralized Threat Center for Swift Zero-day Response

Retrieved on:

Wednesday, March 20, 2024

ASM, Environment, Risk, Research, TEL, Risk management

TEL AVIV, Israel, March 20, 2024 (GLOBE NEWSWIRE) -- IONIX today announced a force multiplier to its industry-leading Attack Surface Management (ASM) platform, a centralized Threat Center to accelerate security teams’ response to newly disclosed zero-days.

Key Points:

TEL AVIV, Israel, March 20, 2024 (GLOBE NEWSWIRE) -- IONIX today announced a force multiplier to its industry-leading Attack Surface Management (ASM) platform, a centralized Threat Center to accelerate security teams’ response to newly disclosed zero-days.
IONIX Threat Center delivers up-to-the-minute detailed insights into exposures posed by the latest zero-day vulnerabilities.
IONIX Threat Center works alongside the company’s recently announced integration of Exposure Validation capabilities .
Key functions of the IONIX Threat Center include:
Zero-Day Threat Identification and Response: Rapidly detects new vulnerabilities exploited in the wild, which are relevant to customers' technology stacks.

Arbe Opens an Office in Shanghai, China, Solidifying the Company’s Presence in the Region

Retrieved on:

Wednesday, March 20, 2024

Rizhao, ITS, Original equipment manufacturer, Perception, Robotics, DiDi, ITMS, Intelligent transportation system, Radar, Safety, TEL, Port, Engineering, Fine chemical

TEL AVIV, Israel, March 20, 2024 - Arbe Robotics Ltd. (NASDAQ: ARBE), a global leader in Perception Radar solutions, today announces that it opened an office in Shanghai, China, solidifying the company’s presence in the region.

Key Points:

TEL AVIV, Israel, March 20, 2024 - Arbe Robotics Ltd. (NASDAQ: ARBE), a global leader in Perception Radar solutions, today announces that it opened an office in Shanghai, China, solidifying the company’s presence in the region.
The strategic move will position Arbe closer to the local OEMs and to the Chinese market, helping the company provide better customer service and position Arbe to gain market share.
Arbe and Weifu High-Technology Group signed a strategic cooperation agreement with KargoBot, DiDi's autonomous freight company, to provide 4D Imaging Radars based on the Arbe proprietary chipset.
The first deployment started at the RiZhao port and will be expanded to additional ports across China.

LightSolver LPU100 Laser Computing System Empowers Enterprises to Solve the Toughest Optimization Problems

Retrieved on:

Tuesday, March 19, 2024

Organization, Risk management, GPU, Vehicle, VMM, Laser, Risk, Quantum computing, Electronics, Senior, Computer, Collection, VRP, TEL

TEL AVIV, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- LightSolver , creator of a new laser-based computing paradigm, today announced a breakthrough in quantum-inspired high-performance computing.

Key Points:

TEL AVIV, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- LightSolver , creator of a new laser-based computing paradigm, today announced a breakthrough in quantum-inspired high-performance computing.
Its LPU100 system unleashes the power of 100 lasers to solve the toughest optimization problems, challenging the processing times of quantum and supercomputers.
The compute capabilities of the LPU100 are now accessible to select enterprise clients through LightSolver’s new cloud platform.
As a purely optical system, the LPU100 overcomes the performance barriers of electronics and can execute mathematical operations at unprecedented speed.